APA (7th ed.) Citation

Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., . . . Subbiah, V. (2022). Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial. The lancet. Oncology, 23(1), . https://doi.org/10.1016/S1470-2045(21)00578-7

Chicago Style (17th ed.) Citation

Wen, Patrick Y., et al. "Dabrafenib Plus Trametinib in Patients with BRAFV600E-mutant Low-grade and High-grade Glioma (ROAR): A Multicentre, Open-label, Single-arm, Phase 2, Basket Trial." The Lancet. Oncology 23, no. 1 (2022). https://doi.org/10.1016/S1470-2045(21)00578-7.

MLA (9th ed.) Citation

Wen, Patrick Y., et al. "Dabrafenib Plus Trametinib in Patients with BRAFV600E-mutant Low-grade and High-grade Glioma (ROAR): A Multicentre, Open-label, Single-arm, Phase 2, Basket Trial." The Lancet. Oncology, vol. 23, no. 1, 2022, https://doi.org/10.1016/S1470-2045(21)00578-7.